AbbVie will offer Calibr research option payments for a period of five years. Credit: AbbVie.

AbbVie has expanded its strategic collaboration with Calibr to advance multiple preclinical and early-stage clinical assets.

These assets belong to AbbVie’s core therapeutic areas, which include neuroscience, oncology and immunology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This partnership represents an extension of the collaboration established by AbbVie and Scripps Research in 2019 to develop potential new therapeutics.

Along with the programmes initially included under the collaboration, which range from the preclinical to the investigational new drug stages of development, Calibr will present a selection of new discovery targets and preclinical assets of mutual interest to AbbVie.

Scripps Research and Calibr president and CEO Peter Schultz stated: “This expansion represents an important step forward in our mission of translating scientific insights and discoveries into innovative, clinically validated drugs, and we believe it is a model for biomedical industry-nonprofit research and development partnerships.”

AbbVie will offer Calibr research option payments for a period of five years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This arrangement is intended to obtain the first exclusive option for developing and commercialising candidates that arise from the independent preclinical research carried out by Calibr. The aim is to advance AbbVie’s pipeline of therapeutic programmes.

If AbbVie chooses to exercise its option for a particular programme, Calibr will be entitled to secure extra payments from AbbVie. These will include option exercise fees, development and commercial milestone payments based on success, and tiered royalties.

AbbVie research and development chief scientific officer and senior vice-president Thomas Hudson stated: “Working together with Calibr, AbbVie is excited to explore and further develop the potential of novel technologies and new clinical indications to bring breakthrough medicines to patients.”